Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?

Jan Paul W R Roovers, Edith A. Sijmons, Jules H Schagen Van Leeuwen, Ben W J Mol, Petronella O. Witteveen, Peter H Th J Slee, A. Peter M Heintz

Research output: Contribution to journalArticle

Abstract

Objective: Suboptimally debulked patients with advanced ovarian cancer who are treated with a combination of cisplatin plus paclitaxel (TP therapy) have a better survival as compared to patients treated with a combination of cisplatin plus cyclophosphamide (CP therapy), but this advantage has not been demonstrated in optimally debulked patients. We performed a retrospective study to compare the effectiveness of TP therapy and CP therapy in optimally debulked patients. Study Design: From 1991 to 1996, 87 consecutive patients with advanced ovarian cancer treated in the University Hospital Utrecht and the St. Antonius Hospital were included in the study. Overall survival (OS) of patients treated with TP or CP were compared. Multivariable Cox-regression analysis was used to calculate a hazard rate ratio (HRR) for OS. Results: In the study period, 51 patients were treated with CP, and 36 patients were treated with TP. In the 18 patients with a tumorrest >2cm, there was a clear, but not statistically significant benefit from TP. In 69 patients with a tumorrest ≤2cm, life expectancy was not increased in patients treated with TP as compared to patients treated with CP (HRR 0.9 (95% CI 0.4-1.9)). Conclusion: We could not show that ovarian cancer patients with residual disease of ≤2cm who were treated with TP had better survival as compared to patients who were treated with CP. Taking into account the high costs of treatment with TP, a randomized trial comparing the effects of TP therapy and CP therapy in optimally debulked patients is warranted.

LanguageEnglish
Pages80-84
Number of pages5
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume97
Issue number1
DOIs
Publication statusPublished - 1 Jan 2001

Keywords

  • Ovarian cancer
  • Paclitaxel
  • Platinum-based chemotherapy

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

Roovers, J. P. W. R., Sijmons, E. A., Van Leeuwen, J. H. S., Mol, B. W. J., Witteveen, P. O., Slee, P. H. T. J., & Heintz, A. P. M. (2001). Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer? European Journal of Obstetrics and Gynecology and Reproductive Biology, 97(1), 80-84. https://doi.org/10.1016/S0301-2115(00)00502-9
Roovers, Jan Paul W R ; Sijmons, Edith A. ; Van Leeuwen, Jules H Schagen ; Mol, Ben W J ; Witteveen, Petronella O. ; Slee, Peter H Th J ; Heintz, A. Peter M. / Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?. In: European Journal of Obstetrics and Gynecology and Reproductive Biology. 2001 ; Vol. 97, No. 1. pp. 80-84.
@article{fb92c092ed93463a8b40d1ae4b1b33ed,
title = "Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?",
abstract = "Objective: Suboptimally debulked patients with advanced ovarian cancer who are treated with a combination of cisplatin plus paclitaxel (TP therapy) have a better survival as compared to patients treated with a combination of cisplatin plus cyclophosphamide (CP therapy), but this advantage has not been demonstrated in optimally debulked patients. We performed a retrospective study to compare the effectiveness of TP therapy and CP therapy in optimally debulked patients. Study Design: From 1991 to 1996, 87 consecutive patients with advanced ovarian cancer treated in the University Hospital Utrecht and the St. Antonius Hospital were included in the study. Overall survival (OS) of patients treated with TP or CP were compared. Multivariable Cox-regression analysis was used to calculate a hazard rate ratio (HRR) for OS. Results: In the study period, 51 patients were treated with CP, and 36 patients were treated with TP. In the 18 patients with a tumorrest >2cm, there was a clear, but not statistically significant benefit from TP. In 69 patients with a tumorrest ≤2cm, life expectancy was not increased in patients treated with TP as compared to patients treated with CP (HRR 0.9 (95{\%} CI 0.4-1.9)). Conclusion: We could not show that ovarian cancer patients with residual disease of ≤2cm who were treated with TP had better survival as compared to patients who were treated with CP. Taking into account the high costs of treatment with TP, a randomized trial comparing the effects of TP therapy and CP therapy in optimally debulked patients is warranted.",
keywords = "Ovarian cancer, Paclitaxel, Platinum-based chemotherapy",
author = "Roovers, {Jan Paul W R} and Sijmons, {Edith A.} and {Van Leeuwen}, {Jules H Schagen} and Mol, {Ben W J} and Witteveen, {Petronella O.} and Slee, {Peter H Th J} and Heintz, {A. Peter M}",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0301-2115(00)00502-9",
language = "English",
volume = "97",
pages = "80--84",
journal = "European Journal of Obstetrics Gynecology and Reproductive Biology",
issn = "0301-2115",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer? / Roovers, Jan Paul W R; Sijmons, Edith A.; Van Leeuwen, Jules H Schagen; Mol, Ben W J; Witteveen, Petronella O.; Slee, Peter H Th J; Heintz, A. Peter M.

In: European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 97, No. 1, 01.01.2001, p. 80-84.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?

AU - Roovers, Jan Paul W R

AU - Sijmons, Edith A.

AU - Van Leeuwen, Jules H Schagen

AU - Mol, Ben W J

AU - Witteveen, Petronella O.

AU - Slee, Peter H Th J

AU - Heintz, A. Peter M

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Objective: Suboptimally debulked patients with advanced ovarian cancer who are treated with a combination of cisplatin plus paclitaxel (TP therapy) have a better survival as compared to patients treated with a combination of cisplatin plus cyclophosphamide (CP therapy), but this advantage has not been demonstrated in optimally debulked patients. We performed a retrospective study to compare the effectiveness of TP therapy and CP therapy in optimally debulked patients. Study Design: From 1991 to 1996, 87 consecutive patients with advanced ovarian cancer treated in the University Hospital Utrecht and the St. Antonius Hospital were included in the study. Overall survival (OS) of patients treated with TP or CP were compared. Multivariable Cox-regression analysis was used to calculate a hazard rate ratio (HRR) for OS. Results: In the study period, 51 patients were treated with CP, and 36 patients were treated with TP. In the 18 patients with a tumorrest >2cm, there was a clear, but not statistically significant benefit from TP. In 69 patients with a tumorrest ≤2cm, life expectancy was not increased in patients treated with TP as compared to patients treated with CP (HRR 0.9 (95% CI 0.4-1.9)). Conclusion: We could not show that ovarian cancer patients with residual disease of ≤2cm who were treated with TP had better survival as compared to patients who were treated with CP. Taking into account the high costs of treatment with TP, a randomized trial comparing the effects of TP therapy and CP therapy in optimally debulked patients is warranted.

AB - Objective: Suboptimally debulked patients with advanced ovarian cancer who are treated with a combination of cisplatin plus paclitaxel (TP therapy) have a better survival as compared to patients treated with a combination of cisplatin plus cyclophosphamide (CP therapy), but this advantage has not been demonstrated in optimally debulked patients. We performed a retrospective study to compare the effectiveness of TP therapy and CP therapy in optimally debulked patients. Study Design: From 1991 to 1996, 87 consecutive patients with advanced ovarian cancer treated in the University Hospital Utrecht and the St. Antonius Hospital were included in the study. Overall survival (OS) of patients treated with TP or CP were compared. Multivariable Cox-regression analysis was used to calculate a hazard rate ratio (HRR) for OS. Results: In the study period, 51 patients were treated with CP, and 36 patients were treated with TP. In the 18 patients with a tumorrest >2cm, there was a clear, but not statistically significant benefit from TP. In 69 patients with a tumorrest ≤2cm, life expectancy was not increased in patients treated with TP as compared to patients treated with CP (HRR 0.9 (95% CI 0.4-1.9)). Conclusion: We could not show that ovarian cancer patients with residual disease of ≤2cm who were treated with TP had better survival as compared to patients who were treated with CP. Taking into account the high costs of treatment with TP, a randomized trial comparing the effects of TP therapy and CP therapy in optimally debulked patients is warranted.

KW - Ovarian cancer

KW - Paclitaxel

KW - Platinum-based chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034929652&partnerID=8YFLogxK

U2 - 10.1016/S0301-2115(00)00502-9

DO - 10.1016/S0301-2115(00)00502-9

M3 - Article

VL - 97

SP - 80

EP - 84

JO - European Journal of Obstetrics Gynecology and Reproductive Biology

T2 - European Journal of Obstetrics Gynecology and Reproductive Biology

JF - European Journal of Obstetrics Gynecology and Reproductive Biology

SN - 0301-2115

IS - 1

ER -